AbbVie, Eisai received new indication approval for Humira to treat pyoderma gangrenosum
AbbVie GK and Eisai Co, Ltd announced an approval of additional indication of Humira, a fully human anti-TNFa monoclonal antibody, for the... Read More
USFDA approved Pfizer’s Abrilada, a biosimilar of Humira
Posted on19 Nov 2019
Comments0
The U.S. Food and Drug Administration (FDA) approved Pfizer’s Abrilada, a biosimilar of Humira. Pfizer said the FDA approved Abrilada (adalimumab-afzb) for the treatment of... Read More
AbbVie, Pfizer’s non-exlcusive licencing agreement for biosimilar Humira
Posted on17 Dec 2018
TagsAbbVie, Amgen, biosimilar of sandoz, Boehringer Ingelheim, Fresenius Kabi, humira, Merck, Momenta, Mylan, novartis, Novartis’ Sandoz, Samsung Bioepis, sandoz
Comments0
AbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries around the world, halting... Read More
Adalimumab Biosimilar Litigation: Sandoz’s settlement with AbbVie
Sandoz, a Novartis division and the global leader in biosimilars, announced a global resolution of all intellectual property (IP) related litigation with... Read More
The European Commission (EC) granted a marketing authorization of IMRALDI®, an adalimumab biosimilar
Posted on26 Aug 2017
TagsAdalimumab, Anti TNF therapy, BENEPALI, Biogen, Biosimilar, FLIXABI, humira, IMRALDI, Samsung Bioepis
Comments0
The European Commission (EC) granted a marketing authorization for IMRALDI® (also known as SB5), an adalimumab biosimilar referencing Humira®. IMRALDI has been... Read More
Amgen’s Amgevita, biosimilar of AbbVie’s Humira (adalimumab), has been approved by the European Commission
Reference Biologic – Humira (adalimumab) of AbbVie Biosimilar – Amgevita (adalimumab) of Amgen European Commission (EC) has granted marketing authorization for AMGEVITA™... Read More
AbbVie’s HUMIRA® (adalimumab) got USFDA Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis
AbbVie, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA® (adalimumab) for the treatment... Read More
Top 5 global pharmaceutical brands by sales
Observations: All top 5 pharmaceutical brands are biopharma products Harvoni approved by USFDA on Oct 10, 2014. It is one of the... Read More
Humira, (adalimumab), Abbvie – 2016 Biggest Patent Expiry and Biosimilar entry
Rheumatoid arthritis treatment Humira has long been a crucial source of revenue for AbbVie: the world’s biggest-selling drug accounted for 63% of... Read More